Q&A: Till­man Gern­gross ex­plains why his Covid mAb will have an edge over an al­ready crowd­ed field

If any­one knows about mon­o­clon­al an­ti­bod­ies, it’s se­r­i­al en­tre­pre­neur, Adimab CEO, and Dart­mouth pro­fes­sor of bio­engi­neer­ing Till­man Gern­gross.

Even the name of Gern­gross’ new an­ti­body start­up Ada­gio Ther­a­peu­tics is meant to re­flect his vi­sion be­hind the de­vel­op­ment of his Covid-19 mAb: slow­ly, he said, ex­plain­ing that “every­one else, whether it’s Re­gen­eron, Lil­ly, or As­traZeneca, Vir, they all val­ued speed over every­thing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER